These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16952623)

  • 61. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
    Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
    Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem.
    Barreto FC; Barreto DV; Moyses RM; Neves CL; Jorgetti V; Draibe SA; Canziani ME; Carvalho AB
    Kidney Int; 2006 May; 69(10):1852-7. PubMed ID: 16612334
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are activated T cells regulators of bone metabolism in children with Crohn disease?
    Sylvester FA; Davis PM; Wyzga N; Hyams JS; Lerer T
    J Pediatr; 2006 Apr; 148(4):461-6. PubMed ID: 16647405
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
    Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
    Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
    Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
    Kazama JJ; Shigematsu T; Yano K; Tsuda E; Miura M; Iwasaki Y; Kawaguchi Y; Gejyo F; Kurokawa K; Fukagawa M
    Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis.
    Szalay F; Hegedus D; Lakatos PL; Tornai I; Bajnok E; Dunkel K; Lakatos P
    J Hepatol; 2003 Apr; 38(4):395-400. PubMed ID: 12663228
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
    Dovio A; Data V; Angeli A
    Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A; Altavilla D; Squadrito G; Romeo A; Adamo EB; Marini R; Inferrera MA; Marini H; Bitto A; D'Anna R; Corrado F; Bartolone S; Frisina N; Squadrito F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
    Suzuki T; Suda N; Ohyama K
    J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.